AB Science announced today that the Canadian Patent Office has issued a Notice of Allowance for a patent relating to methods of treating amyotrophic lateral sclerosis (ALS) with its lead compound, masitinib (CA 3018635).

This new Canadian patent provides strong protection for masitinib in the treatment of ALS until 2037, and completes the Company's intellectual property position in ALS in all
geographical areas where masitinib could be marketed.

In addition to patent protection, masitinib can also benefit
from regulatory data protection in Canada, which prevents generic competition for a period of eight years from initial market authorization.

Masitinib has also received orphan drug designation for ALS from both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). This orphan drug designation confers 10 and 7 years respectively of market exclusivity in
Europe and the United States from the time of product registration.



Copyright (c) 2023 CercleFinance.com. All rights reserved.